Enliven Therapeutics, Inc. (NASDAQ:ELVN - Get Free Report) CEO Samuel Kintz sold 12,000 shares of the firm's stock in a transaction dated Thursday, April 25th. The shares were sold at an average price of $16.89, for a total value of $202,680.00. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink.
Samuel Kintz also recently made the following trade(s):
- On Thursday, April 11th, Samuel Kintz sold 47,709 shares of Enliven Therapeutics stock. The shares were sold at an average price of $25.04, for a total value of $1,194,633.36.
- On Monday, March 25th, Samuel Kintz sold 12,000 shares of Enliven Therapeutics stock. The shares were sold at an average price of $17.56, for a total value of $210,720.00.
Enliven Therapeutics Price Performance
Shares of NASDAQ ELVN traded up $0.61 during midday trading on Monday, reaching $17.79. The company's stock had a trading volume of 283,528 shares, compared to its average volume of 230,641. The stock has a market capitalization of $832.75 million, a P/E ratio of -8.12 and a beta of 1.06. The firm has a 50 day moving average price of $17.12 and a 200-day moving average price of $14.50. Enliven Therapeutics, Inc. has a 12-month low of $9.80 and a 12-month high of $26.00.
Enliven Therapeutics (NASDAQ:ELVN - Get Free Report) last posted its quarterly earnings results on Thursday, March 14th. The company reported ($0.47) EPS for the quarter, topping analysts' consensus estimates of ($0.56) by $0.09. On average, equities analysts predict that Enliven Therapeutics, Inc. will post -2.16 EPS for the current year.
Analyst Upgrades and Downgrades
Separately, Mizuho began coverage on Enliven Therapeutics in a research note on Tuesday, April 9th. They issued a "buy" rating and a $34.00 target price on the stock.
Check Out Our Latest Research Report on ELVN
Institutional Investors Weigh In On Enliven Therapeutics
A number of hedge funds and other institutional investors have recently bought and sold shares of the business. SG Americas Securities LLC grew its position in shares of Enliven Therapeutics by 17.8% during the 4th quarter. SG Americas Securities LLC now owns 13,501 shares of the company's stock valued at $187,000 after purchasing an additional 2,041 shares in the last quarter. Mirae Asset Global Investments Co. Ltd. grew its position in shares of Enliven Therapeutics by 9.1% during the 4th quarter. Mirae Asset Global Investments Co. Ltd. now owns 12,305 shares of the company's stock valued at $170,000 after purchasing an additional 1,029 shares in the last quarter. Exchange Traded Concepts LLC grew its position in shares of Enliven Therapeutics by 34.0% during the 4th quarter. Exchange Traded Concepts LLC now owns 8,708 shares of the company's stock valued at $121,000 after purchasing an additional 2,208 shares in the last quarter. China Universal Asset Management Co. Ltd. grew its position in shares of Enliven Therapeutics by 67.0% during the 1st quarter. China Universal Asset Management Co. Ltd. now owns 7,952 shares of the company's stock valued at $140,000 after purchasing an additional 3,189 shares in the last quarter. Finally, AJOVista LLC purchased a new position in shares of Enliven Therapeutics during the 4th quarter valued at $28,000. Institutional investors own 95.08% of the company's stock.
About Enliven Therapeutics
(
Get Free Report)
Enliven Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on the discovery and development of small molecule inhibitors to help patients with cancer. The company's lead product candidates comprise ELVN-001, which is being evaluated in a Phase 1 clinical trial in adults with chronic myeloid leukemia; and ELVN-002, a Phase 1 clinical trial in adults with solid tumors with HER2 alterations.
Recommended Stories
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider Enliven Therapeutics, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Enliven Therapeutics wasn't on the list.
While Enliven Therapeutics currently has a "Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Wondering what the next stocks will be that hit it big, with solid fundamentals? Click the link below to learn more about how your portfolio could bloom.
Get This Free Report
